Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1852 1
1920 1
1932 1
1934 1
1935 1
1938 1
1939 1
1942 1
1945 1
1946 5
1947 9
1948 13
1951 1
1952 2
1954 1
1955 1
1956 3
1957 1
1958 2
1959 4
1960 2
1961 5
1962 7
1963 7
1964 13
1965 12
1966 17
1967 7
1968 3
1969 13
1970 5
1971 8
1972 10
1973 9
1974 6
1975 11
1976 5
1977 8
1978 9
1979 9
1980 15
1981 16
1982 6
1983 17
1984 27
1985 22
1986 24
1987 25
1988 17
1989 16
1990 24
1991 22
1992 14
1993 14
1994 12
1995 25
1996 15
1997 25
1998 32
1999 42
2000 39
2001 43
2002 30
2003 36
2004 40
2005 29
2006 28
2007 26
2008 34
2009 30
2010 24
2011 51
2012 45
2013 42
2014 39
2015 51
2016 51
2017 55
2018 73
2019 63
2020 73
2021 97
2022 105
2023 83
2024 72
2025 72

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,831 results

Results by year

Filters applied: . Clear all
Page 1
Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide.
Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, Metterville J, Shin M, Sanil N, Dooley C, Puri A, Weiss A, Wightman N, Gray-Edwards H, Marosfoi M, King RM, Kenderdine T, Fabris D, Bowser R, Watts JK, Brown RH Jr. Tran H, et al. Among authors: watts jk. Nat Med. 2022 Jan;28(1):117-124. doi: 10.1038/s41591-021-01557-6. Epub 2021 Dec 23. Nat Med. 2022. PMID: 34949835 Free PMC article.
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. de Botton S, et al. Among authors: watts jm. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Blood Adv. 2023. PMID: 36724515 Free PMC article.
Increasing intracellular dNTP levels improves prime editing efficiency.
Liu P, Ponnienselvan K, Nyalile T, Oikemus S, Joynt AT, Iyer S, Kelly K, Guo D, Kyawe PP, Vanderleeden E, Redick SD, Huang L, Chen Z, Lee JM, Schiffer CA, Harlan DM, Wang JP, Emerson CP Jr, Lawson ND, Watts JK, Sontheimer EJ, Luban J, Wolfe SA. Liu P, et al. Among authors: watts jk. Nat Biotechnol. 2025 Apr;43(4):539-544. doi: 10.1038/s41587-024-02405-x. Epub 2024 Sep 25. Nat Biotechnol. 2025. PMID: 39322763 Free PMC article.
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein A, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT. DiNardo CD, et al. Among authors: watts jm. Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302. Blood Adv. 2024. PMID: 38640348 Free PMC article. Clinical Trial.
Yoga, cognitive-behavioural therapy versus education to improve quality of life and reduce healthcare costs in people with endometriosis: a randomised controlled trial.
Mikocka-Walus A, Druitt M, O'Shea M, Skvarc D, Watts JJ, Esterman A, Tsaltas J, Knowles S, Harris J, Dowding C, Parigi E, Evans S. Mikocka-Walus A, et al. Among authors: watts jj. BMJ Open. 2021 Aug 9;11(8):e046603. doi: 10.1136/bmjopen-2020-046603. BMJ Open. 2021. PMID: 34373298 Free PMC article. Clinical Trial.
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Steensma DP, et al. Among authors: watts jm. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. Leukemia. 2021. PMID: 34172893 Free PMC article. Clinical Trial.
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.
Shneider NA, Harms MB, Korobeynikov VA, Rifai OM, Hoover BN, Harrington EA, Aziz-Zaman S, Singleton J, Jamil A, Madan VR, Lee I, Andrews JA, Smiley RM, Alam MM, Black LE, Shin M, Watts JK, Walk D, Newman D, Pascuzzi RM, Weber M, Neuwirth C, Da Cruz S, Soriano A, Lane R, Henry S, Mathews J, Jafar-Nejad P, Norris D, Rigo F, Brown RH, Miller S, Crean R, Bennett CF. Shneider NA, et al. Among authors: watts jk. Lancet. 2025 Jun 7;405(10494):2075-2086. doi: 10.1016/S0140-6736(25)00513-6. Epub 2025 May 22. Lancet. 2025. PMID: 40414239
Olutasidenib: from bench to bedside.
Venugopal S, Watts J. Venugopal S, et al. Among authors: watts j. Blood Adv. 2023 Aug 22;7(16):4358-4365. doi: 10.1182/bloodadvances.2023009854. Blood Adv. 2023. PMID: 37196640 Free PMC article. Review.
1,831 results